openPR Logo
Press release

Antibacterial Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024

10-27-2017 02:23 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Antibacterial Drugs Market - Global Industry Insights, Trends,

Prevalence of bacterial infections and diseases is especially high in third world countries and significantly hampers quality of life across the globe. Further adding to the woes of the affected population is the increasing strains of bacteria that are resistant to conventional antibacterial drugs. The epidemic of antibacterial resistance has spurred interest among the global healthcare organizations and a few pharmaceutical companies and research institutes to develop next-generation antibacterial drugs to effectively thwart such maladies. Unregulated and over prescription of antibacterial drugs has led to increased drug resistance. Moreover, genetic mutations are considered to be another major reason for antibacterial drug resistance. Ironically, these factors have greatly constrained the growth of antibacterial drugs market for years.

Request a sample pdf Copy of report @ https://www.coherentmarketinsights.com/insight/request-sample/177

Invention of Penicillin was a major breakthrough for treating bacterial infections. This stimulated research for more antibacterial drugs to treat different bacteria such as Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus (MRSA) and Enterococcus species. However, price control and decreasing financial incentives discouraged pharmaceutical companies to conduct further research in this field. This has limited treatment options for bacterial infections, while discovery of new strains of infectious bacteria is on rise. Below is the timeline of antibacterial drug discovery:

Antibacterial Drugs Market

The timeline highlights the large void in introduction of new antibacterial drugs during period 1960–2000. Streptomycin, sulfonamide, macrolide, nalidixic acid, aminoglycoside, tetracycline, and linezolid are among the bacterial resistant drugs.

Prospective drug candidates in research to improve the future outlook of the global antibacterial drugs market

The global antibacterial drugs market potential is estimated based on the current antibacterial drug classes, including those mentioned above and those in clinical trials. As of March 2016, there are around 37 drugs in clinical development for treating serious bacterial infections. These drugs are intended to be primarily launched in the U.S.

Moreover, FDA is encouraging development of new antibacterial drugs by laying out guidelines for the industry on the types of clinical studies to be conducted on antibacterial drug evaluation. This factor coupled with various incentives for research companies would create a positive outlook for the global antibacterial drugs resistance market in the near future.

Also, in March 2017, the WHO released a list of pathogens, classified based on the criticality/urgency, for which newer antibacterial drugs are required. The different environmental forces working towards development of newer antibacterial drugs would be a major continuing factor for the global antibacterial drugs market growth.

Alarming rise in drug resistant strains of bacteria driving awareness initiatives and programs by global healthcare organizations to back companies in the antibacterial drugs market

According to the Centers for Drug Disease Prevention and Control (CDC), every year at least 2 million people in the U.S. acquire bacterial infections that are resistant to drugs. Antibacterial resistance results in 23,000 deaths every year in the U.S. Moreover, according to the European Antimicrobial Resistance Surveillance Network (EARS-Net) data of November 2016, antibiotic resistance is higher in southern and south-eastern Europe than in northern Europe.

Multiple drug resistance, as in case of tuberculosis, has further aggravated the treatment for specific conditions. According to the World health Organization (WHO), India has the highest burden of TB worldwide. Furthermore, the MDR-TB cases resistant to second-line drugs was 16% among already treated cases reported in 2015. Globally, an estimated 480,000 people developed MDR-TB in 2015 (WHO). The Government of India has drafted a national Strategic Plan 2017-2025 for eradicating TB in India. This would further propel the antibacterial drugs market in India.

Ask for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/177

The WHO has carved a ‘Global Action Plan on Antimicrobial Resistance’ in 2015 to fight against growing antibacterial resistance. CDC is also working in close collaboration with healthcare providers, pharmaceuticals companies, farmers, agriculture and environmental specialists, and representatives from Federal agencies to monitor, and control the prescription and use of antibacterial drugs. Such initiatives are expected to hold drugs for the future generation until the new drug launch and thus drive the antibacterial drugs market.

Some of the major players in the global antibacterial drugs market are Pfizer, Inc., Johnson & Johnson, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Evotec Pharmaceuticals, Allecra Therapeutics, Kyorin Pharmaceutical, and Allergan plc.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights
E-mail : sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibacterial Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024 here

News-ID: 790627 • Views:

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic foot ulcers treatment market
Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017 – 2025
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2025 globally
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for Antibacterial

Antibacterial Masks Market 2021 | Detailed Report
Global Antibacterial Masks Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and Figures)
Global Antibacterial Drugs Market - Forecasts to 2026
According to a new market research report published by Global Market Estimates, the Global Antibacterial Drugs Market will expand at a CAGR value of 4.2% to reach USD 41.5 billion by 2026. The increasing demand for efficient and inexpensive antibacterial drugs, and also the increasing number of multi-drug resistant bacterial strains, are some of the primary factors driving the market growth. Browse 117 Market Data Tables and 117 Figures spread through
Magniflex Introduces Antiviral and Antibacterial Collection
Magniflex, the renowned mattress manufacturer from Italy, has always had innovation in its DNA, as the success, accolades, and certifications obtained over the years prove, and the goal has always been to introduce innovative solutions to common issues that affect the quality of our sleep. As a response to the COVID-19 global pandemic, Magniflex conducted scientific and technological research in collaboration with prominent experts in order to produce MagniProtect: an
Antibacterial Filter Market - Key Development by 2027
Antibacterial Filter Market 2020 report focuses on the major drivers and restraints for the Global key players. It also provides analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The recent research report on the global Antibacterial Filter market presents the latest industry data and future trends, allowing you to recognize the products and end users driving Revenue growth and profitability of the market. The report
Global Antibacterial Drugs Market Research Report
This report studies the global Antibacterial Drugs market status and forecast, categorizes the global Antibacterial Drugs market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bayer AG Pfizer Inc. Sanofi GlaxoSmithKline Plc. (GSK) Merck & Co., Inc. AstraZeneca Johnson and Johnson Bristol
Global Antibacterial Drugs Market: Regional Overview
The global antibacterial drugs market features a fairly competitive landscape and leading players include Allergan, Plc., Novartis AG, Bristol Myers Squibb Company, Johnson and Johnson, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi, Pfizer Inc., Bayer AG, notes Transparency Market Research (TMR). Over the years, the competition in the market is expected to intensify. A number of prominent players are focusing on entering into strategic collaborations and mulling